Targeting activated JAK1/2 with Ruxo selectively suppresses IFNγR1KO but not scrambled control melanomas, coupled with enhanced effector functions (e.g., TNF production) and reduced Treg frequency in TILs. This evidence concerns the gene JAK1 and melanoma.